Unite and Conquer Cancer

ASCO 2019

The ASCO (American Society of Clinical Oncology) organization provides an excellent platform for education of oncology professionals, promoting cancer research and advocating patients who suffer from cancer.

Every year, the ASCO Annual Meeting takes place at the McCormick Place in Chicago, Illinois with the goal of conquering cancer by uniting more than 40,000 scientist and medical professionals from all over the world.

This year I had the opportunity to visit this massive scientific meeting which was held between May 31 and June 4 2019.

Here are the most important abstracts that were presented in melanoma topic:

  • A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma (ASCO abstract # 9504)

Adjuvant treatment of resected stage III and stage IV melanoma patients with low-dose ipilimumab showed superior overall survival as compared to patients who were treated with high-dose interferon. The full results are published here.

  • Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs) (ASCO abstract # 9500)

The researchers concluded that “After local treatment of one to three melanoma brain metastases, adjuvant WBRT does not provide clinical benefit in terms of distant intracranial control, survival, or preservation of performance status.” (Hong et al, JCO, 2019). The full results are published here.

  • Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T) (ASCO abstract # 9510)

The authors here investigated whether changing plasma levels of mutant BRAF ctDNA could detect tumor progression in unresectable stage III and stage IV melanoma patients who were treated with D or D+T. The researchers found that those patients whose ctDNA became undetectable within the first 4 weeks of treatment had prolonged survival as compared to those patients whose ctDNA remained detectable.

ASCO 2019 was a great!

It was surely a great experience to attend such an intense meeting with a very comprehensive agenda. I also had the opportunity to present my research during a poster session (ASCO abstract # 9548). The discussion was intense and I am glad for all the feedback I got from the researchers who were interested in my work.

Finally, I am happy that I could return to this great city and had the chance once again to enjoy the beautiful view from the Signature Lounge at the 96th floor (picture above).













Renata Varaljai, ESR15